Evaluation of the mycophenolate mofetil–rituximab combination in systemic sclerosis: a French retrospective multicenter study (MycRiSSc)
F. Barde(Inserm), Benjamin Chaigne(Centre National de la Recherche Scientifique), Kévin Chevalier(Inserm), Anne Murarasu(Hôpital Necker-Enfants Malades), Luc Mouthon(Université Paris Cité), G. Pugnet(Hôpital Rangueil), A. Renaud(Université d'Angers), Alban Deroux(Centre Hospitalier Universitaire de Grenoble), Pierre Charles(Institute Mutualiste Montsouris), Cyrille Coustal(Université de Montpellier), Martin Michaud(Hôpital Notre-Dame), F Maillet(Université Paris Cité), Paul Decker, Emmanuel Chatelus(Laboratoire National de Référence), J. Lodovichetti(Centre Hospitalier de Douai), Alain Lescoat(Inserm), Vincent Koether(Centre Hospitalier Universitaire de Lille), B. Granel(Inserm), Alexandre Maria(Université de Montpellier), Sébastien Rivière(Sorbonne Université), Claire de Moreuil(Centre Hospitalier Régional Universitaire de Brest)
Cited by 4
Related Papers
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
Mapping and predicting mortality from systemic sclerosis
|Annals of the Rheumatic Diseases|2017|699
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes
|Journal of the European Academy of Dermatology and Venereology|2017|261